靶向YAP1可改善子宫内膜异位症中的孕激素抵抗
本研究通过人子宫内膜异位症组织与血清样本及小鼠模型,发现YAP1通过上调miR-21-5p抑制孕激素受体(PGR)表达并损害蜕膜化;YAP1抑制剂维替泊芬(VP)可降低miR-21-5p、升高PGR并增强孕激素疗效,地诺孕素治疗6个月可降低血清细胞外囊泡相关miR-21-5p水平。
要点
- YAP1通过上调miR-21-5p抑制PGR表达并损害子宫内膜基质细胞蜕膜化。
- YAP1抑制剂维替泊芬在小鼠模型中增加PGR表达、增强蜕膜化并协同孕激素促进病灶消退。
- 地诺孕素治疗6个月可显著降低患者血清细胞外囊泡相关miR-21-5p水平。
核心结论
- YAP1抑制在体外和体内均可减轻孕激素抵抗。
- YAP1与PGR的相互调节提示YAP1抑制剂联合孕激素可能成为治疗子宫内膜异位症的更佳方法。
研究设计与样本
- 分析含配对子宫内膜异位症与子宫内膜标本的石蜡包埋组织(n=42),以及正常对照(n=15)、接受过(n=25)或未接受过(n=21)地诺孕素治疗的子宫内膜异位症患者的血清样本。
- 使用子宫内膜异位症小鼠模型评估YAP1抑制对孕激素抵抗的影响。
- 体外研究使用原代子宫内膜异位症与子宫内膜基质细胞,以YAP1抑制剂或miR-21模拟物/抑制剂处理,进行蜕膜化诱导、染色质免疫沉淀(ChIP)和RNA免疫沉淀。
- 人和小鼠的组织标本与血清分别用于免疫组化染色、外泌体分离和微小RNA(miRNA)定量。
主要发现
- ChIP-PCR和RNA-IP显示YAP1通过上调miR-21-5p抑制孕激素受体(PGR)表达。
- miR-21-5p上调不仅降低PGR表达,还抑制子宫内膜基质细胞蜕膜化。
- 人子宫内膜样本中YAP1和miR-21-5p水平与PGR水平呈负相关。
- 敲低YAP1或用YAP1抑制剂维替泊芬(VP)处理可降低异位子宫内膜异位症基质细胞中miR-21-5p表达,从而增加PGR表达。
- 小鼠子宫内膜异位症模型中,VP治疗增加PGR表达并增强蜕膜化;VP协同增加孕激素促进子宫内膜异位病灶消退的疗效并改善子宫内膜蜕膜化能力。
关键数值与推荐
- 接受地诺孕素治疗6个月的患者血清细胞外囊泡相关miR-21-5p水平显著下降。
- 地诺孕素治疗可降低人细胞和小鼠子宫内膜异位症模型中YAP1和miR-21-5p表达。
临床怎么用
- 作者认为YAP1抑制剂联合孕激素可能成为治疗子宫内膜异位症的更佳治疗策略。
局限性
- 未来研究需要大样本临床样本来验证miR-21-5p目前的诊断价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does YAP1 inhibition alleviate progesterone resistance in endometriosis? SUMMARY ANSWER: YAP1 inhibition reduces progesterone resistance in vitro and in vivo. WHAT IS KNOWN ALREADY: Progesterone resistance not only causes treatment failure for endometriosis but also inhibits eutopic endometrial cell proliferation, dysregulates decidualization, and reduces the success rates of pregnancy. Hippo/yes-associated protein 1 (YAP1) signaling pathway plays an important role in the pathogenesis of endometriosis. STUDY DESIGN, SIZE, DURATION: Paraffin-embedded tissues containing paired endometriotic and endometrial specimens (n = 42) and serum samples isolated from normal controls (n = 15) or endometriotic patients with (n = 25) or without (n = 21) prior dienogest treatment were analyzed. A mouse model of endometriosis was also used to evaluate the effects of YAP1 inhibition on progesterone resistance. PARTICIPANTS/MATERIALS, SETTING, METHODS: Primary endometriotic and endometrial stromal cells treated with YAP1 inhibitor or miR-21 mimic/inhibitor were used for the in vitro studies including decidualization induction, chromatin immunoprecipitation (ChIP), and RNA immunoprecipitation. Tissue specimens and serum from human and mouse were used for immunohistochemistry staining, exosome isolation, and microRNA (miRNA) quantification, respectively. MAIN RESULTS AND THE ROLE OF CHANCE: Herein, we report, by using ChIP-PCR and RNA-IP, that YAP1 inhibits progesterone receptor (PGR) expression through upregulation of miR-21-5p. Upregulation of miR-21-5p not only reduces PGR expression but also inhibits endometrial stromal cell decidualization. Indeed, levels of YAP1 and miR-21-5p are inversely correlated with the level of PGR in human endometrial samples. In contrast, knockdown of YAP1 or treatment with verteporfin (VP), a YAP1 inhibitor, reduces miR-21-5p expression, thus leading to an increase in PGR expression in ectopic endometriotic stromal cells. In the mouse model of endometriosis, treatment with VP increases PGR expression and enhances decidualization. More importantly, VP synergistically increases the treatment effect of progestin in causing the regression of endometriotic lesions and improves the decidualization capability of the endometrium. Interestingly, treatment with dienogest, a synthetic progestin, reduces YAP1 and miR-21-5p expression in human cells and in the mouse model of endometriosis. Patients who received dienogest treatment for 6 months show a significant decrease in serum extracellular vesicle-associated miR-21-5p level. LARGE SCALE DATA: A public dataset (GSE51981) containing a large cohort of endometriotic tissues is available from the Gene Expression Omnibus (GEO). LIMITATIONS, REASONS FOR CAUTION: A large cohort of clinical samples is needed to verify the current diagnostic value of miR-21-5p in future studies. WIDER IMPLICATIONS OF THE FINDINGS: The reciprocal regulation of YAP1 and PGR suggests that combined YAP1 inhibitor and progestin may be a better therapeutic approach for treating endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Ministry of Science and Technology, Taiwan (MOST-111-2636-B-006-012, MOST-111-2314-B-006-075-MY3, and MOST-106-2320-B-006-072-MY3). The authors have no conflict of interest to disclose.
引用
- Lin SC, Li WN, Lin SC, et al. Targeting YAP1 ameliorates progesterone resistance in endometriosis. Hum Reprod. 2023. PMID: 37071897. doi:10.1093/humrep/dead071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。